Recent Updates
Recently added Catalysts
EQ Positive Sentiment

Equillium to Participate in the 38th Annual Roth Conference

Wednesday, March 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Equillium, Inc. will participate in the 38th Annual Roth Conference on March 23, 2026. The management team will be available for investor meetings, showcasing their commitment to investor engagement. The company focuses on developing therapies for severe autoimmune and inflammatory disorders, with their lead candidate EQ504 showing promise in treating conditions like ulcerative colitis.
Price reaction · baseline $2.15 (2026-03-17 close) · hit after-hours · clean, no other EQ news in the window
day 0 close · peak
-0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Equillium is participating in a notable industry conference.
  • Management will engage with investors, indicating strong investor relations.
  • The company is innovating in treatments for severe autoimmune and inflammatory disorders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+58%
120-day peak, hindsight
Typical move
2.1%
average across 2 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
BNZ132-1-40
Phase 1 · Safety and Tolerability in Healthy Subjects

Full Press Release Details

LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38thAnnual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT.
Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.
About EquilliumEquillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. EQ504 is an investigational therapeutic program with potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.
For more information, visitwww.equilliumbio.com.

Investor ContactPJ KelleherLifeSci Advisors, LLC+1-617-430-7579pkelleher@lifesciadvisors.com

Frequently Asked Questions

When is Equillium participating in the Roth Conference?

Equillium will participate in the Roth Conference on March 23, 2026.

What is EQ504?

EQ504 is Equillium's lead therapeutic candidate for treating severe autoimmune disorders.

Who can meet with Equillium's management at the conference?

Registered investors attending the conference can meet with Equillium's management.

What type of therapies is Equillium developing?

Equillium is developing novel therapies for severe autoimmune and inflammatory disorders.

ShareAdd on Google
Tags: EQ Viatris Investor Conferences Healthcare Equillium Roth Conference EQ504 autoimmune disorders biotechnology
Last updated: Mar 18, 2026

Biotech snapshot

Cash runway
$57M liquidity · $1M/mo burn
~42 mo
Minimal dilution risk
Lead asset
BNZ132-1-40Phase 1
Safety and Tolerability in Healthy Subjects →

Catalyst track record

+58%
best trade around EQ's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for EQ.

See every catalyst's timing & PoA →